Comparative evaluation of radionuclide therapy using 90Y and 177Lu

• Published in: Annals of nuclear medicine Vol. 37; no. 1; pp. 52 - 59
• Main Authors: Hanaoka, Hirofumi, Hashimoto, Kazuyuki, Watanabe, Satoshi, Matsumoto, Shojiro, Sakashita, Tetsuya, Watanabe, Shigeki, Ishioka, Noriko S., Endo, Keigo
• Format: Journal Article
• Language: English
• Published: Singapore Springer Nature Singapore 2023; Springer Nature B.V
• Subjects: Antibodies; Emitters; Evaluation; Growth rate; Half-life; Imaging; Lutetium isotopes; Medicine; Medicine & Public Health; Monte Carlo simulation; Nuclear Medicine; Original Article; Radiation; Radiation dosage; Radiation therapy; Radioisotopes; Radiology; Tumor cell lines; Tumors; Yttrium isotopes; Radionuclide therapy; Y; Lu; Tumor growth rate
• ISSN: 0914-7187; 1864-6433
• DOI: 10.1007/s12149-022-01803-y

Objective
Both
90
Y and
177
Lu are attractive β-emitters for radionuclide therapy and have been used in clinical practice. Nevertheless, comparative evaluation between
90
Y- and
177
Lu-labeled molecules has not been fully conducted. Thus, in this study, the features of
90
Y and
177
Lu for radionuclide therapy were assessed in tumor-bearing mice.
Methods
Two tumor cell lines with different growth rates were used. Biodistribution studies of
177
Lu-labeled antibodies (
177
Lu-Abs) were conducted in each tumor-bearing mouse model. Subsequently, the therapeutic effect of
90
Y- and
177
Lu-Ab were assessed in tumor-bearing mice. The absorbed radiation dose for the tumor was estimated using the Monte Carlo simulation.
Results
177
Lu-Abs demonstrated high tumor accumulation in both tumor-xerograph. In the fast-growing tumor model,
90
Y-Ab showed a better therapeutic effect than
177
Lu-Ab, reflecting a higher absorbed radiation dose of
90
Y-Ab than that of
177
Lu-Ab. In the slow-growing tumor model, both
90
Y- and
177
Lu-Ab showed an excellent therapeutic effect; however,
177
Lu-Ab had a longer efficacy period than
90
Y-Ab, which could be attributed to the longer half-life and better dose uniformity of
177
Lu than those of
90
Y.
Conclusions
To accomplish a maximum therapeutic effect, selecting
90
Y or
177
Lu, to depend on the growth rate of individual cancer, would be helpful.